Participation in a post-discharge rehabilitation program after valve surgery was associated with a 34% relative decrease in hospitalization during the first year and a 61% relative decrease in mortality at one year.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Valve Disease
November 2, 2019
October 12, 2019
Excellent document from the EACTS, STS, and AATS emphasizing the importance of standardization of prosthetic heart valve labeling.
October 10, 2019
Reporting of postmarket outcomes for the Sapien 3 and Mitraclip devices frequently misclassified patient deaths as device malfunction or other outcomes. Misclassification for Sapien 3 involved 17.5% of patient deaths, and involved 24.7% of patient deaths for Mitraclip.
October 8, 2019
An interesting pilot experiment on attempting to quantify the optimum disposition of neochordae in transapical intervention for severe mitral regurgitation.
October 6, 2019
The authors address appropriate use of the transcatheter clip to treat degenerative mitral regurgitation in elderly low to moderate risk patients.
August 29, 2019
Using an approach that minimizes valve depth relative to the membranous septum, the authors reduced the need for permanent pacemaker placement to a reliable and predictable 3% compared to the accepted standard of 10%.
August 25, 2019
In an era of increased use of MitraClip, surgical mitral valve repair still offers a durable solution. Tirone David and colleages report 1,234 consecutive patients who had mitral valve repair with 20 year follow-up.
August 16, 2019
The FDA-approved use of TAVR has now expanded to low-risk patients with severe aortic stenosis. This includes both Edwards Lifesciences' Sapien 3 and Sapien 3 Ultra as well as Medtronic's Evolut R and Evolut PRO.
August 11, 2019
Colleagues from Italy and Germany compared the short- and mid-term outcomes of the straight tube graft (David-I) and the Valsalva graft in 232 patients undergoing an isolated David procedure. The two groups did not differ significantly in 30-day mortality (1% vs 2%), late survival (p = 0.799), or valve-related reoperation (p = 0.241).
August 9, 2019
Retrospectively using a longitudinal echocardiography database, the authors analyzed the data of 3,276 patients with isolated severe tricuspids regurgitation (TR) from 2001 through 2016. Of these patients, 5% underwent tricuspid valve surgery.